Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2013 1
2014 4
2015 1
2016 2
2017 4
2018 4
2019 7
2020 4
2021 6
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case.
Vallacchi V, Vergani E, Cossa M, Gargiuli C, Busico A, Devecchi A, Dugo M, Bergamaschi L, De Cecco L, Cavalieri S, Valeri B, Tamborini E, Gallino G, Del Vecchio M, Santinami M, Sensi M, Rivoltini L, Di Guardo L, Rodolfo M. Vallacchi V, et al. Among authors: di guardo l. J Immunother Cancer. 2024 Jan 4;12(1):e007612. doi: 10.1136/jitc-2023-007612. J Immunother Cancer. 2024. PMID: 38177075 Free PMC article.
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
Goodman RS, Di Guardo L, Maurichi A, Kirwin B, Khattak A, Vanella V, Lee J, Lawless A, Czapla J, Spagnoletti A, Ambrosini M, Livingstone E, Long GV, Sullivan RJ, Carlino MS, Atkinson V, Trojanello C, Ascierto PA, Schadendorf D, Warburton L, Menzies AM, Santinami M, Johnson DB. Goodman RS, et al. Among authors: di guardo l. Eur J Cancer. 2023 Nov;194:113354. doi: 10.1016/j.ejca.2023.113354. Epub 2023 Sep 22. Eur J Cancer. 2023. PMID: 37827067
Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA, Di Giacomo AM, Chiarion Sileni V, Queirolo P, Spagnolo F, De Galitiis F, Cognetti F, Mandalà M, Guidoboni M, Rinaldi G, Depenni R, Consoli F, Troiani T, Guida M, Marconcini R, Ferrucci PF, Strippoli S, Fava P, Merelli B, Simeone E, Di Guardo L, Giannarelli D, Maio M, Quaglino P, Del Vecchio M. Ascierto PA, et al. Among authors: di guardo l. Eur J Cancer. 2023 Sep;191:113246. doi: 10.1016/j.ejca.2023.113246. Epub 2023 Jul 19. Eur J Cancer. 2023. PMID: 37549531
Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma.
Vandoni G, D'Amico F, Fabbrini M, Mariani L, Sieri S, Casirati A, Di Guardo L, Del Vecchio M, Anichini A, Mortarini R, Sgambelluri F, Celano G, Serale N, De Angelis M, Brigidi P, Gavazzi C, Turroni S. Vandoni G, et al. Among authors: di guardo l. Int J Mol Sci. 2023 Jul 18;24(14):11611. doi: 10.3390/ijms241411611. Int J Mol Sci. 2023. PMID: 37511376 Free PMC article.
Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian tertiary cancer center.
Fucà G, Lecchi M, Ciniselli CM, Ottini A, Spagnoletti A, Mazzeo L, Morelli D, Frati P, Stroscia M, Ebrahem E, Sottotetti E, Galli G, D'Elia MG, Lobefaro R, Ducceschi M, Di Guardo L, Bhoori S, Provenzano S, Platania M, Niger M, Colombo E, Nichetti F, Duca M, Rivoltini L, Mortarini R, Baili P, Apolone G, de Braud F, Verderio P, Damian S. Fucà G, et al. Among authors: di guardo l. Ther Adv Med Oncol. 2022 Jul 27;14:17588359221108687. doi: 10.1177/17588359221108687. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35923922 Free PMC article.
Fertility preservation for patients with melanoma.
Filippi F, Serra N, Vigano P, Boeri L, Cimminiello C, Di Guardo L, Somigliana E, Del Vecchio M. Filippi F, et al. Among authors: di guardo l. Melanoma Res. 2022 Oct 1;32(5):303-308. doi: 10.1097/CMR.0000000000000840. Epub 2022 Jul 19. Melanoma Res. 2022. PMID: 35855660
Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles.
Vergani E, Busico A, Dugo M, Devecchi A, Valeri B, Cossa M, Di Guardo L, De Cecco L, Feltrin E, Valle G, Deho P, Frigerio S, Lalli L, Gallino G, Del Vecchio M, Santinami M, Pruneri G, Tamborini E, Rivoltini L, Sensi M, Vallacchi V, Rodolfo M. Vergani E, et al. Among authors: di guardo l. J Invest Dermatol. 2022 Nov;142(11):3030-3040.e5. doi: 10.1016/j.jid.2022.04.027. Epub 2022 May 26. J Invest Dermatol. 2022. PMID: 35643181 Free article.
44 results